Best-value biological medicines: Tocilizumab
The Medicines Management Programme has identified a best-value biological (BVB) medicine for medicinal products containing tocilizumab on the High Tech Arrangement.
The MMP recommends the following as a BVB medicine for tocilizumab on the High Tech Arrangement:
- Tyenne® (Fresenius Kabi Ireland)
A copy of the MMP Evaluation Report is available in the Related Files section below.
The MMP recommends that:
- all new patients being initiated on treatment with tocilizumab on the High Tech Arrangement should be prescribed the BVB medicine
- patients currently established on treatment with tocilizumab on the High Tech Arrangement should be considered for switching to the BVB medicine at the earliest possible opportunity.
Resources to support prescribing of the BVB medicine are located in the Related Files section below:
- MMP Communication - BVB Medicine Tocilizumab 19 December 2025
- BVB Tocilizumab Questions & Answers for Healthcare Professionals
- BVB Reimbursement of Tocilizumab Q and A for Healthcare Professionals
- BVB Tocilizumab Patient Information
- BVB Tyenne Product Information Sheet
- BVB Tocilizumab Patient and Clinic Support Services.
For further information, please contact mmp@hse.ie.